Auro Labs.

Which are the latest news on Auro Labs.?

Why is Auro Laboratories Ltd falling/rising?

As of 05-Jul, Auro Laboratories Ltd's stock price is at 255.00, showing a slight increase of 0.31%. However, it has underperformed against the Sensex in recent periods, with declining investor participation and mixed performance indicators suggesting potential challenges ahead.

As of 05-Jul, Auro Laboratories Ltd's stock price is currently at 255.00, reflecting a change of 0.8 (0.31%) upwards. Despite this slight increase, the stock has shown mixed performance over various periods. In the past week, it has underperformed the benchmark Sensex, which rose by 0.86%, while the stock itself increased by only 0.49%. Over the last month, Auro Laboratories Ltd has seen a decline of 3.00%, contrasting with the Sensex's gain of 4.60%. <BR><BR>Year-to-date, the stock has a modest increase of 2.22%, while the Sensex has decreased by 8.75%. However, over the longer term, the stock has performed significantly better, with a 212.96% increase over three years, compared to the Sensex's 19.26%. <BR><BR>Today's performance indicates that the stock has underperformed its sector by 1.19%. Additionally, the stock's moving averages show that it is higher than the 5-day and 200-day averages but lower than the 20-day, 50-day, and 100-day averages, suggesting some volatility in its recent price movements. <BR><BR>Moreover, there has been a notable decline in investor participation, with delivery volume dropping by 93.96% against the 5-day average, indicating reduced trading interest. While the stock remains liquid enough for trading, these factors combined suggest that despite a slight rise in price today, Auro Laboratories Ltd is facing challenges that could affect its overall performance moving forward.

How big is Auro Labs.?

As of 10th June, Auro Laboratories Ltd has a market capitalization of 165.00 Cr, classifying it as a Micro Cap company, with recent net sales of 14.71 Cr and a net profit of 0.97 Cr. The company reports shareholder's funds of 42.97 Cr and total assets of 99.10 Cr.

As of 10th June, Auro Laboratories Ltd has a market capitalization of 165.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, Auro Laboratories Ltd reported Net Sales of 14.71 Cr and a Net Profit of 0.97 Cr. This performance reflects the company's financial activity over the recent periods.<BR><BR>The latest annual reporting period for Auro Laboratories Ltd shows Shareholder's Funds of 42.97 Cr and Total Assets amounting to 99.10 Cr. These figures provide insight into the company's financial health and stability.

Who are in the management team of Auro Labs.?

The management team of Auro Labs includes Sharat Deorah (Chairman & Managing Director), Siddhartha Deorah (Whole-time Director), Kiran Kulkarni (Whole-time Director), and several Independent Directors: Goverdhandas Aggarwal, Kailash Chandra Bubna, Kavita Vijayakant Sharma, and Vishal Kailash Chandra Jhunjhunwala, along with Sweta Agarwal as Company Secretary & Compliance Officer. They oversee the company's operations and strategic direction.

The management team of Auro Labs includes the following individuals:<BR><BR>1. **Sharat Deorah** - Chairman & Managing Director<BR>2. **Siddhartha Deorah** - Whole-time Director<BR>3. **Goverdhandas Aggarwal** - Independent Director<BR>4. **Kailash Chandra Bubna** - Independent Director<BR>5. **Kavita Vijayakant Sharma** - Independent Director<BR>6. **Kiran Kulkarni** - Whole-time Director<BR>7. **Sweta Agarwal** - Company Secretary & Compliance Officer<BR>8. **Vishal Kailash Chandra Jhunjhunwala** - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Auro Labs.?

Auro Labs.'s peers include Kimia Bioscien., Natural Capsules, Achyut Healthcar, Panch. Organics, Parnax Lab, Krebs Biochem, Quest Laborato., and Accretion Pha. In terms of performance, Achyut Healthcar leads with a 71.17% return, while Auro Labs. has a -10.52% return, better than Natural Capsules at -35.45%.

Peers: Auro Labs., Kimia Bioscien., Natural Capsules, Achyut Healthcar, Panch.Organics, Parnax Lab, Krebs Biochem, Quest Laborato., Accretion Pha.<BR><BR>Quality Snapshot: Excellent management risk is observed at Accretion Pha. and Quest Laborato., while Average management risk is found at Auro Labs. and Panch.Organics. Below Average management risk is noted for Kimia Bioscien., Natural Capsules, and the rest. Growth is rated as Excellent for Achyut Healthcar and Accretion Pha., Good for Parnax Lab and Quest Laborato., Average for Auro Labs., and Below Average for Kimia Bioscien., Natural Capsules, and the rest. Capital Structure is Excellent for Panch.Organics and Parnax Lab, Good for Achyut Healthcar and Accretion Pha., and Below Average for Kimia Bioscien., Natural Capsules, and the rest.<BR><BR>Return Snapshot: Achyut Healthcar has the highest 1-year return at 71.17%, while Natural Capsules has the lowest at -35.45%. Auro Labs.'s 1-year return is -10.52%, which is better than Natural Capsules but worse than Achyut Healthcar. Additionally, Kimia Bioscien., Natural Capsules, Panch.Organics, Krebs Biochem, and Parnax Lab all have negative six-month returns.

What does Auro Labs. do?

Auro Laboratories Ltd is a micro-cap pharmaceutical company founded in 1992, specializing in generic Active Pharmaceutical Ingredients, particularly anti-diabetics like Metformin HCL. As of March 2026, it reported net sales of 10 Cr and a net profit of 1 Cr, with a market cap of INR 165 Cr.

Overview: <BR>Auro Laboratories Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of generic Active Pharmaceutical Ingredients (API), particularly Anti Diabetics like Metformin HCL.<BR><BR>History: <BR>Auro Laboratories Ltd was founded in 1992. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Net Sales: 10 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 165 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 44.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.33 <BR>Return on Equity: 7.82% <BR>Price to Book: 3.49<BR><BR>Contact Details: <BR>Address: K-56 MIDC Indl Area, Tarapur Boisar Thane Maharashtra : 401506 <BR>Tel: 91-22-66635456 <BR>Email: auro@aurolabs.com <BR>Website: http://www.aurolabs.com

Should I buy, sell or hold Auro Laboratories Ltd?

When is the next results date for Auro Laboratories Ltd?

The next results date for Auro Laboratories Ltd is 29 May 2026.

The next results date for Auro Laboratories Ltd is scheduled for 29 May 2026.

Are Auro Laboratories Ltd latest results good or bad?

Auro Laboratories Ltd's latest Q2 FY26 results show a significant operational turnaround with a net profit of ₹0.72 crore and a 219.13% revenue increase. However, long-term challenges like declining sales, low return on equity, and a high P/E ratio suggest caution for investors.

Auro Laboratories Ltd's latest results for Q2 FY26 indicate a significant operational turnaround, showcasing both positive and concerning aspects. The company reported a net profit of ₹0.72 crore, marking a recovery from a loss in the previous quarter. Additionally, revenue surged by 219.13% quarter-on-quarter to ₹8.84 crore, which is a remarkable improvement.<BR><BR>The operating margin also improved dramatically to 26.70%, up from just 0.72% in Q1 FY26, reflecting better cost management and operational efficiency. However, despite these positive indicators, the company faces serious long-term challenges, including a five-year sales decline of -13.87% annually and a concerning return on equity (ROE) of only 10.30%, which is below the industry average.<BR><BR>Moreover, the company's high P/E ratio of 157.30x raises questions about its valuation, especially given the structural issues it faces. The elevated debt levels and minimal institutional interest further complicate the outlook.<BR><BR>In summary, while the latest quarterly results show a strong recovery, the underlying structural challenges and high valuation suggest caution for investors.

How has been the historical performance of Auro Labs.?

Auro Labs reported a net profit of 1.84 crore and total operating income of 19.40 crore for the year ending March 2025, with a profit after tax margin of 9.48% and an operating profit margin of 17.58%. Total liabilities increased to 99.10 crore, driven by long-term borrowings of 30.79 crore, while shareholder's funds grew to 42.97 crore.

Answer:<BR>The historical performance of Auro Labs shows a consolidated net profit of 1.84 crore for the year ending March 2025, with total operating income of 19.40 crore. The operating profit margin, excluding other income, stands at 17.58%, while the profit after tax margin is 9.48%. The company has total liabilities of 99.10 crore, with long-term borrowings increasing significantly to 30.79 crore from previous years. The total assets have also risen to 99.10 crore, reflecting growth in shareholder's funds, which reached 42.97 crore. <BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Auro Labs reported a total operating income of 19.40 crore, with a net profit of 1.84 crore, indicating a profit after tax margin of 9.48%. The operating profit, excluding other income, was 3.41 crore, leading to an operating profit margin of 17.58%. The company's total liabilities increased to 99.10 crore, driven by a rise in long-term borrowings to 30.79 crore. Shareholder's funds grew to 42.97 crore, supported by total reserves of 36.74 crore. The total assets also saw an increase, reaching 99.10 crore, while the cash flow from operating activities was reported at 5.00 crore, reflecting a net cash outflow of 1.00 crore for the year.

Is Auro Labs. overvalued or undervalued?

As of February 17, 2025, Auro Labs is considered very expensive and overvalued, with a PE Ratio of 113.15 and an EV to EBITDA of 60.60, significantly higher than its peers, despite a recent 1-year stock return of 35.93% compared to the Sensex's 7.60%.

As of 17 February 2025, Auro Labs has moved from an expensive to a very expensive valuation grade. The company is currently overvalued based on its financial metrics. Key ratios include a PE Ratio of 113.15, an EV to EBITDA of 60.60, and a Price to Book Value of 4.18, which significantly exceed those of its peers. For instance, Sun Pharma has a PE Ratio of 35.25 and an EV to EBITDA of 24.91, while Divi's Lab shows a PE of 79.33 and an EV to EBITDA of 57.35, both indicating that Auro Labs is trading at a premium compared to these competitors.<BR><BR>In addition to its high valuation ratios, Auro Labs has a ROCE of 8.79% and a ROE of 3.69%, which do not justify its elevated price levels. The company has outperformed the Sensex in recent periods, with a 1-year stock return of 35.93% compared to the Sensex's 7.60%, yet this strong performance does not mitigate the overvaluation indicated by its financial ratios.

What is the technical trend for Auro Labs.?

As of May 13, 2025, Auro Labs has shifted to a bullish trend with strong indicators, including bullish MACD and Bollinger Bands on both weekly and monthly time frames, despite a mildly bearish KST signal, and has outperformed the Sensex with a 10.98% gain over the past week and 19.19% over the past month.

As of 13 May 2025, the technical trend for Auro Labs has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend on both time frames. The daily moving averages are bullish, reinforcing the positive outlook. However, the KST shows a mildly bearish signal on the monthly, and Dow Theory indicates a mildly bullish stance on the monthly with no trend on the weekly. Overall, the strength of the bullish trend is supported by the recent price action, with the stock returning 10.98% over the past week and 19.19% over the past month, significantly outperforming the Sensex.

Who are the top shareholders of the Auro Labs.?

The top shareholders of Auro Labs include Auro Impex Private Ltd with 18.75%, individual investors with 36.57%, and Kirtilaben Jayantilal Mehta as the highest public shareholder at 3.13%. There are no pledged promoter holdings or foreign institutional investors, and mutual funds hold only 0.01%.

The top shareholders of Auro Labs include the promoters, with Auro Impex Private Ltd holding the largest stake at 18.75%. Additionally, individual investors collectively own 36.57% of the company. The highest public shareholder is Kirtilaben Jayantilal Mehta, who holds 3.13%. There are no pledged promoter holdings, and the company does not have any foreign institutional investors (FIIs) involved. Mutual funds have a minimal presence, with only one scheme holding 0.01%.

Has Auro Labs. declared dividend?

No Dividend History Available